Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Annette Diehl

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Arthritis Research & Therapy|October 16, 2020
Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinibVibeke Strand, Jeffrey Kaine, Rieke Alten, et al.
Biomolecular NMR Assignments|July 29, 2009
Backbone and sidechain 1H, 13C and 15N resonance assignments of the RGS domain from human RGS14Elizabeth F Dowler, Annette Diehl, Peter Schmieder, et al.
The Journal of Rheumatology|December 3, 2016
Safety and Efficacy of SBI-087, a Subcutaneous Agent for B Cell Depletion, in Patients with Active Rheumatoid Arthritis: Results from a Phase II Randomized, Double-blind, Placebo-controlled StudyNemanja Damjanov, Malgorzata Tlustochowicz, Jacob Aelion, et al.
Journal of Clinical Pharmacology|October 25, 2013
Reassessment of tigecycline bone concentrations in volunteers undergoing elective orthopedic proceduresIndranil Bhattacharya, Mark H Gotfried, Allena J Ji, et al.
The American Journal of Gastroenterology|September 26, 2025
Pregnancy Outcomes After Maternal or Paternal Exposure to Tofacitinib Across Clinical ProgramsUma Mahadevan, María Chaparro, Michelle Segovia, et al.
Structure (London, England : 1993)|March 15, 2011
The structure of MESD45-184 brings light into the mechanism of LDLR family foldingChristian Köhler, Janet K Lighthouse, Tobias Werther, et al.
RMD Open|June 9, 2021
Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift)Stanley B Cohen, Janet Pope, Boulos Haraoui, et al.
Clinical Pharmacology and Therapeutics|March 28, 2022
Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous BiomarkersManoli Vourvahis, Wonkyung Byon, Cheng Chang, et al.
The Lancet. Rheumatology|January 17, 2024
Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trialStanley B Cohen, Janet Pope, Boulos Haraoui, et al.
Therapeutic Advances in Musculoskeletal Disease|March 13, 2025
Tofacitinib in early active axial spondyloarthritis: protocol of a randomized double-blind, placebo-controlled, multicenter phase IV study, FASTLANEValeria Rios Rodriguez, Lidia Sánchez-Riera, Hildrun Haibel, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Arthritis Research & Therapy|October 16, 2020
Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinibVibeke Strand, Jeffrey Kaine, Rieke Alten, et al.
Biomolecular NMR Assignments|July 29, 2009
Backbone and sidechain 1H, 13C and 15N resonance assignments of the RGS domain from human RGS14Elizabeth F Dowler, Annette Diehl, Peter Schmieder, et al.
The Journal of Rheumatology|December 3, 2016
Safety and Efficacy of SBI-087, a Subcutaneous Agent for B Cell Depletion, in Patients with Active Rheumatoid Arthritis: Results from a Phase II Randomized, Double-blind, Placebo-controlled StudyNemanja Damjanov, Malgorzata Tlustochowicz, Jacob Aelion, et al.
Journal of Clinical Pharmacology|October 25, 2013
Reassessment of tigecycline bone concentrations in volunteers undergoing elective orthopedic proceduresIndranil Bhattacharya, Mark H Gotfried, Allena J Ji, et al.
The American Journal of Gastroenterology|September 26, 2025
Pregnancy Outcomes After Maternal or Paternal Exposure to Tofacitinib Across Clinical ProgramsUma Mahadevan, María Chaparro, Michelle Segovia, et al.
Structure (London, England : 1993)|March 15, 2011
The structure of MESD45-184 brings light into the mechanism of LDLR family foldingChristian Köhler, Janet K Lighthouse, Tobias Werther, et al.
RMD Open|June 9, 2021
Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift)Stanley B Cohen, Janet Pope, Boulos Haraoui, et al.
Clinical Pharmacology and Therapeutics|March 28, 2022
Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous BiomarkersManoli Vourvahis, Wonkyung Byon, Cheng Chang, et al.
The Lancet. Rheumatology|January 17, 2024
Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trialStanley B Cohen, Janet Pope, Boulos Haraoui, et al.
Therapeutic Advances in Musculoskeletal Disease|March 13, 2025
Tofacitinib in early active axial spondyloarthritis: protocol of a randomized double-blind, placebo-controlled, multicenter phase IV study, FASTLANEValeria Rios Rodriguez, Lidia Sánchez-Riera, Hildrun Haibel, et al.
Pageof 3